BMC Cancer (Mar 2023)

Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"

  • Christine Deutschmann,
  • Christian F. Singer,
  • Daphne Gschwantler-Kaulich,
  • Georg Pfeiler,
  • Carmen Leser,
  • Pascal A. T. Baltzer,
  • Thomas H. Helbich,
  • Christine Kraus,
  • Ricarda Korbatits,
  • Alaa Marzogi,
  • Paola Clauser

DOI
https://doi.org/10.1186/s12885-023-10764-y
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background Residual fibroglandular breast tissue (RFGT) following a mastectomy has been claimed to be associated with the occurrence of an in-breast local recurrence (IBLR) or new primary tumor (NP). Yet, scientific evidence proving this assumption is lacking. The primary aim of the study was to verify whether RFGT following a mastectomy is a risk factor for an IBLR or NP. Methods This retrospective analysis included all patients that underwent a mastectomy and were followed up at the Department of Obstetrics and Gynecology of the Medical University of Vienna between 01.01.2015 and 26.02.2020. RFGT volume (assessed on magnetic resonance imaging) was correlated with the prevalence of an IBLR and a NP. Results A total of 105 patients (126 breasts) following a therapeutic mastectomy were included. After a mean follow-up of 46.0 months an IBLR had occurred in 17 breasts and a NP in 1 breast. A significant difference in RFGT volume was observed between the disease-free cohort and the subgroup with an IBLR or NP (p = .017). A RFGT volume of ≥ 1153 mm3 increased the risk by the factor 3.57 [95%CI 1.27; 10.03]. Conclusions RFGT volume is associated with an increased risk for an IBLR or NP.

Keywords